Fasting Mimicking Diet Protocol: Valter Longo's 5-Day Plan

Quick answer: The fasting mimicking diet (FMD) is a 5-day, low-calorie (~800 kcal/day), very-low-protein, high-fat dietary protocol designed by Dr. Valter Longo at USC that activates fasting biology without complete food deprivation. A human RCT (Longo 2016, Science Translational Medicine, n=100) demonstrated that 3 monthly FMD cycles reduced body weight, blood glucose, IGF-1, blood pressure, cholesterol, and CRP — with the greatest benefits in participants with elevated baseline risk factors.

What Is the Fasting Mimicking Diet?

The fasting mimicking diet is not intermittent fasting, time-restricted eating, or caloric restriction. It is a specific 5-consecutive-day protocol with precisely calibrated macronutrient ratios — very low protein (<10% of calories), moderate carbohydrate (~45%), and high fat (~45%) — engineered to activate the cellular pathways of fasting while providing enough nutrition to allow continued work and function during the protocol.

The protocol was developed by Dr. Valter Longo, director of the USC Longevity Institute and the IFOM Institute of Molecular Oncology in Milan, over more than two decades of research beginning with yeast lifespan extension studies, progressing through mouse longevity and cancer trials, and culminating in multiple human clinical trials. The commercialized version (ProLon) has completed clinical trials and is available through physician ordering.

The fundamental logic: the mechanisms activated by fasting — autophagy, stem cell regeneration, IGF-1 suppression, ketone production, and senescent cell clearance — require multiple consecutive days of nutrient deprivation to reach full activation. Single-day fasts or daily time-restriction activate these pathways incompletely. The FMD protocol provides the minimum duration needed for maximum pathway activation while limiting the protein intake that would signal mTOR and suppress autophagy even at caloric restriction.

The Molecular Mechanisms of FMD

IGF-1 Suppression and FOXO3 Activation

Insulin-like growth factor 1 (IGF-1) is the primary mediator of the growth-versus-longevity trade-off in biology. High IGF-1 drives cell growth, proliferation, and anabolic processes — but also accelerates aging, cancer cell proliferation, and suppresses stress resistance pathways. Dietary protein is the primary dietary regulator of IGF-1 — specifically methionine and branched-chain amino acids that signal hepatic IGF-1 production.

Morgan Levine (now Yale) published a landmark analysis in Cell Metabolism (2014) using NHANES data (n=6,381) demonstrating that high animal protein intake (>20% of calories) in middle-aged adults (ages 50–65) was associated with a 74% increased risk of all-cause mortality and a 4-fold increase in cancer mortality — an association mediated by IGF-1 levels and abolished after age 65 (when adequate protein becomes protective). The protein-IGF-1-cancer axis is one of the most important but least publicized findings in nutritional epidemiology.

FMD’s very-low-protein constraint (<10% of calories, typically 15–20g protein over 5 days) produces dramatic IGF-1 suppression — reductions of 30–40% from baseline measurable within the 5-day protocol. Low IGF-1 activates FOXO3 transcription factors — found in every human centenarian population studied — which drive expression of stress resistance, DNA repair, and longevity-associated genes. FOXO3 activation simultaneously suppresses NF-κB inflammatory signaling.

Autophagy Induction

Autophagy — the cellular process of sequestering and degrading damaged organelles, misfolded proteins, and intracellular debris — is maximally induced by nutrient deprivation, specifically by low protein/amino acid availability (via mTOR inhibition) and low glucose (via AMPK activation). Both conditions are achieved by day 2–3 of the FMD protocol.

Autophagy induction on FMD is evidenced by upregulation of ATG7, Beclin-1, and LC3-II — the core autophagy execution machinery — measurable in circulating peripheral blood mononuclear cells from FMD subjects. For conditions driven by autophagy failure — neurodegenerative disease, lysosomal dysfunction, accumulation of protein aggregates — the FMD-induced autophagy pulse represents a potentially disease-modifying intervention beyond what is achievable with daily time-restricted eating or short fasts.

Stem Cell Regeneration

Cheng et al. published a pivotal study in Cell Stem Cell (2014) demonstrating that prolonged fasting cycles (2–4 day fasts) in mice depleted old, damaged immune cells and — critically — upon refeeding, activated hematopoietic stem cells to regenerate a fresh, younger immune system. The mechanism: prolonged fasting reduces PKA signaling (via low IGF-1 and glucose) and suppresses mTOR, together creating the conditions for stem cell dormancy followed by robust activation upon nutrient availability.

Notably, fasting cycles in chemotherapy patients (small human pilot, Cheng 2014) produced a rebound increase in lymphocyte count and progenitor cells post-fasting, suggesting the immune regenerative mechanism operates in humans. This is the basis for FMD use in oncology as a chemotherapy adjunct — FMD before chemotherapy cycles may protect healthy cells via differential stress resistance while simultaneously regenerating a depleted immune system between cycles.

Senescent Cell Clearance

Prolonged fasting activates NK cells and cytotoxic T cells with enhanced immune surveillance capacity. These immune effectors are responsible for much of the body’s natural senolytic activity — recognizing and eliminating senescent cells displaying SASP markers on their surface. FMD’s immune activation phase (combined with the autophagy-driven internal degradation of senescent cells) provides a physiological senolytic mechanism complementary to pharmacological senolytics like dasatinib + quercetin or fisetin.

In mouse models of aging, monthly FMD cycles reduced senescent cell burden across multiple tissues and improved age-related functional decline. Human data on senescent cell clearance specifically from FMD is limited but mechanistically supported; the 37% senescent T-cell reduction seen from HBOT (Hachmo 2020) and estimated reductions from FMD likely target overlapping senescent cell populations through complementary mechanisms.

The Human Clinical Trial Evidence

The Longo 2016 RCT (Science Translational Medicine)

The most cited FMD human trial enrolled 100 adults randomized to 3 monthly FMD cycles versus a continuous normal diet control. The FMD protocol: day 1 at ~1,100 kcal (10% protein, 56% fat, 34% carbohydrate); days 2–5 at ~725 kcal (9% protein, 44% fat, 47% carbohydrate). After 3 monthly cycles:

Body weight: −2.6 kg (vs. −0.6 kg control). Lean muscle mass was preserved — the weight loss was predominantly from fat mass and visceral fat. BMI: −1.0 kg/m² in the FMD group. Waist circumference: significant reduction vs. control. Fasting glucose: −4.1 mg/dL reduction. IGF-1: −5.7 ng/mL reduction. Systolic blood pressure: −4.5 mmHg. Total cholesterol: −4.4 mg/dL. LDL cholesterol: −5.8 mg/dL. CRP (inflammatory marker): significant reduction in participants with elevated baseline CRP. These effects were most pronounced in participants starting with elevated risk factors — those with normal baseline values showed minimal change, while those with metabolic syndrome criteria showed substantial improvements.

The TRIIM Trial (Nature Aging, 2019)

Greg Fahy and colleagues published the Thymus Regeneration, Immunorestoration and Insulin Mitigation (TRIIM) trial in Nature Aging (2019) — a pilot study using a combination of recombinant human GH, DHEA, metformin, zinc, and vitamin D in nine healthy men aged 51–65. The primary finding was unexpected and extraordinary: the intervention reversed biological age by an average of 2.5 years on the Horvath clock, with progressive reversal over the 12-month protocol. Thymic regeneration was confirmed on MRI. While not a pure FMD study, the protocol included IGF-1 management elements conceptually overlapping with Longo’s approach, and the biological age reversal was independently confirmed by multiple epigenetic clock algorithms including Hannum and a composite clock analysis.

FMD in Multiple Sclerosis and Autoimmune Conditions

Choi et al. (2016, Cell Reports) demonstrated in mouse models of MS that FMD cycles produced axonal remyelination, immune system regeneration with shift toward anti-inflammatory phenotypes, and functional neurological improvement — effects not seen with a ketogenic diet or caloric restriction alone. A small pilot in human MS patients showed tolerability and promising trends in immune markers. A larger RCT is ongoing at USC.

In lupus mouse models, FMD cycles suppressed autoimmune disease activity and extended survival. The mechanism — resetting an autoreactive immune system through the fasting-stem cell regeneration cycle — provides a compelling rationale for FMD in autoimmune conditions including rheumatoid arthritis, inflammatory bowel disease, and psoriasis, though human clinical trial evidence for these indications remains preliminary.

FMD Protocol: DIY vs. ProLon

The FMD can be implemented through the commercialized ProLon kit (available through physician recommendation) or through a careful DIY approach replicating the macronutrient ratios.

ProLon (L-Nutra): A 5-day food kit providing pre-portioned, ready-to-eat plant-based foods (soups, bars, crackers, olives, teas, and supplements) at the precise macronutrient ratios validated in clinical trials. Day 1: ~1,100 kcal. Days 2–5: ~725 kcal each. All food is vegan, plant-based, and low in protein. The kit includes a micro-nutrient supplement to prevent deficiencies during the 5-day restriction. Cost: ~$190–$250 per 5-day box. Physician ordering available through the L-Nutra website.

DIY FMD macros (days 2–5): 700–750 total calories. Protein: <10% (~15–18g). Fat: 44–47% (~35–38g). Carbohydrate: 45–48% (~80–85g). No animal protein. Suitable foods include: vegetable soups (low-protein broth-based), small amounts of nuts (macadamia, almond), olives, coconut products (high fat), low-sugar berries in very small amounts, green vegetables, herbal teas, water, black coffee without additives. Avoid: any animal products, legumes in quantity (protein content), protein shakes or supplements. The protein constraint is non-negotiable — even small amounts of animal protein significantly blunt IGF-1 suppression and mTOR inhibition.

Refeeding day 6: The refeeding day is as important as the fast itself. Aggressive carbohydrate refeeding post-fast activates insulin and IGF-1 at the exact moment stem cell proliferation is maximal, driving stem cell activation and tissue regeneration. A moderate, balanced refeeding with adequate carbohydrate and protein is recommended — not a continuation of restriction. Longo’s protocol recommends a Mediterranean-style refeeding pattern.

Dosing Frequency

Longo’s clinical trial used monthly FMD cycles (1 FMD per month for 3 months), which is appropriate for individuals with significant metabolic dysfunction, elevated cardiovascular risk, inflammatory conditions, or a desire for accelerated biological change. For healthy individuals in longevity maintenance mode, quarterly FMD (4 cycles per year) appears to provide meaningful biological rejuvenation without the compliance burden of monthly cycles.

Longo himself has publicly stated he performs the FMD twice yearly as a maintenance protocol. For individuals actively working to reverse metabolic dysfunction, improve epigenetic age, or manage autoimmune disease, monthly cycles for 3–6 months followed by quarterly maintenance is the most evidence-aligned approach.

FMD in the Functional Medicine Context

The FMD fits naturally into a functional medicine protocol as a quarterly or monthly intensive intervention to complement ongoing dietary and lifestyle practices:

Paired with Mediterranean diet: The Mediterranean diet (olive oil, fish, vegetables, legumes, whole grains, minimal red meat) lowers IGF-1 modestly throughout the year. The FMD provides quarterly deep IGF-1 suppression surges that the Mediterranean diet cannot achieve with chronic low-level restriction alone. Together, they address the IGF-1 axis at multiple timepoints and intensity levels.

Synergy with senolytics: FMD’s immune regeneration cycle and senolytic NK/T cell activation is mechanistically complementary to pharmacological senolytics. Scheduling an FMD cycle during or after a D+Q or fisetin pulse potentially amplifies senescent cell clearance — the pharmacological senolytic destabilizes the senescent cell anti-apoptotic machinery while the FMD-enhanced immune system eliminates them. No clinical trial has evaluated this combination, but the mechanistic logic is compelling.

Paired with NAD+ precursors: NAD+ supports the SIRT1 and SIRT3 longevity pathways that are upregulated by caloric restriction and fasting. Continuing NMN or NR supplementation through FMD cycles supports the sirtuin activation that amplifies fasting’s mitochondrial and epigenetic benefits.

Pre-FMD biomarker timing: Testing biological age (TruDiagnostic), metabolic panels, and inflammatory markers before and after a quarterly FMD protocol provides objective outcome measurement — the most rigorous way to confirm biological response and justify continued protocol adherence.

Contraindications and Precautions

The FMD requires physician supervision and is not appropriate for all individuals:

Absolute contraindications: Active eating disorder or history of anorexia nervosa (FMD may reinforce restrictive patterns). Type 1 diabetes or insulin-dependent type 2 diabetes (insulin dosing during FMD requires close physician management — hypoglycemia risk). Pregnancy or breastfeeding. Underweight status (BMI <18.5). Active cancer without oncology guidance (although FMD as chemotherapy adjunct may be appropriate under oncology supervision).

Relative contraindications / requires physician supervision: Type 2 diabetes managed with sulfonylureas or GLP-1 agonists (medication adjustment needed during restriction). History of syncope or cardiac arrhythmia. Chronic kidney disease (protein restriction already present — further restriction may be inappropriate). Active inflammatory bowel disease flare. Age <18 or >70 without geriatric evaluation (evidence base is primarily in middle-aged adults).

Common manageable side effects: Headache and fatigue on days 2–3 (typically transient, peak at day 3 — the “fasting flu”). Mild hunger (typically manageable with herbal teas and adequate water intake). Electrolyte imbalances (mitigated by sodium supplementation — 1–2g sodium as broth on days 2–5). Sleep disruption in some individuals. All resolve with refeeding.

FAQs About the Fasting Mimicking Diet

Is the fasting mimicking diet the same as intermittent fasting?
No — they are fundamentally different interventions. Intermittent fasting (16:8, 5:2, alternate-day) involves recurring daily or weekly restriction patterns. The FMD is a specific 5-consecutive-day protocol with precisely calibrated macronutrient ratios (very low protein, moderate carbohydrate, high fat) designed to reach the cellular biology of multi-day fasting. Intermittent fasting does not typically reduce IGF-1 significantly in the fed window, does not achieve the depth of autophagy seen after 3+ days of fasting, and does not trigger the stem cell regeneration cycle activated by prolonged multi-day nutrient deprivation. The FMD is done monthly or quarterly, not daily — it is an intensive periodic intervention, not a daily eating pattern.

Will the fasting mimicking diet cause muscle loss?
The Longo 2016 clinical trial specifically measured lean body mass and found that lean mass was preserved while fat mass was reduced. The preservation mechanism involves the FMD’s very low protein intake combined with adequate fat and carbohydrate — the body prioritizes fat oxidation for energy rather than amino acid catabolism when sufficient calories are available from fat. Post-FMD refeeding with adequate protein (0.8–1.2 g/kg/day) is important to support any stem-cell-driven tissue regeneration. Most adults doing monthly FMD cycles do not experience clinically significant muscle loss; those with low lean mass should confirm baseline body composition before initiating monthly cycles.

Can you exercise during the fasting mimicking diet?
Light activity (walking, gentle yoga, mild stretching) is appropriate during the FMD and may enhance fat oxidation and ketone production. Intense exercise — strength training, HIIT, long-duration endurance workouts — is not recommended during the 5-day restriction phase due to the caloric deficit and risk of hypoglycemia, excessive cortisol response, and muscle breakdown at restricted caloric intake. Return to full training on day 6 and beyond. Timing FMD in training cycles during a planned rest or deload week optimizes both FMD biology and training periodization.

What happens if you eat protein during the fasting mimicking diet?
Even modest protein intake blunts the core mechanisms that make FMD effective. Dietary protein (especially methionine and branched-chain amino acids) activates mTORC1 — directly suppressing autophagy — and stimulates hepatic IGF-1 production within 2–4 hours of consumption. A meal containing 25–30g protein during the FMD protocol effectively ends autophagy activation and blunts IGF-1 suppression for the remainder of the day. The protein constraint (<10% of calories, typically 15–20g over 5 days) is non-negotiable for biological efficacy. This is why animal products — even “healthy” sources like eggs, fish, or lean chicken — must be eliminated for the full 5 days.

If you are considering the fasting mimicking diet as part of a longevity, metabolic optimization, or autoimmune management protocol, proper medical evaluation including baseline metabolic labs, body composition, medication review, and cardiac history is essential before beginning. Our functional medicine practice provides the comprehensive evaluation and ongoing monitoring that maximizes FMD safety and outcomes. Call us at (810) 206-1402 to schedule a longevity consultation.

Fasting Mimicking Diet (FMD): Longo Protocol, Science, and Longevity Benefits